Skip navigation

Novel Strategies for Balancing Cost, Access and Quality for Next-Generation Therapies

October 2-3, 2018
  • Amsterdam, The Netherlands

CBI’s Advanced Therapies Commercialisation Congress is a collaborative, multi-stakeholder meeting for exchanging views and exploring business approaches for the evolving ATMP segment. This congress convenes industry executives, public policy makers, academia and other professionals in the advanced therapies community to address the key barriers and exciting opportunities on the journey to commercialisation of these innovative technologies.

JOIN OUR LIST FOR PROGRAM UPDATES!

A Dialogue-Driven Forum on Key Issues and the Path Forward for Advanced Therapies:

  • Review significant recent and the expected upcoming
    events in the ATMP space
  • Weigh the pros and cons of EU-accelerated clinical
    development and market access pathways
  • Hear case studies from industry pioneers throughout the world
  • Draw insights from ATMPs that have been commercialised to
    date to inform future market access strategies
  • Anticipate what technologies and infrastructure will be
    needed in the future to mainstream ATMPs
  • Learn about recent pricing and reimbursement strategies
    for cell and gene therapies in the EU and US
  • Deliberate over the real-world challenges and approaches
    to defining and demonstrating therapy value

Download the Conference Preview

Previous Attendee Acclaim:

A great line-up of speakers and the conference
atmosphere enabled excellent discussion.

Global Head, Pricing, Market Access & Policy, Biosimilars, Merck

Excellent conference to bring the commercial and
government contracting perspectives together.

Dept. Director, Government Contracts & Reporting, Bayer

This was a great opportunity to network and share
best practices in our very specialized field.

Finance Manager, Janssen Pharmaceuticals

Every speaker, without exception was excellent.

Director, Patient-Focused Drug Development, TESARO

The robust discussion from all attendees was insightful
and provocative. Rare to have at a conference and
really made it a valuable engagement.

Consumer Marketing Leader, Respiratory, AstraZeneca

Advanced Therapies Commercialisation Congress

Novel Strategies for Balancing Cost, Access and Quality for Next-Generation Therapies

CBI’s Advanced Therapies Commercialisation Congress is a collaborative, multi-stakeholder meeting for exchanging views and exploring business approaches for the evolving ATMP segment. This congress convenes industry executives, public policy makers, academia and other professionals in the advanced therapies community to address the key barriers and exciting opportunities on the journey to commercialisation of these innovative technologies.

JOIN OUR LIST FOR PROGRAM UPDATES!

A Dialogue-Driven Forum on Key Issues and the Path Forward for Advanced Therapies:

  • Review significant recent and the expected upcoming
    events in the ATMP space
  • Weigh the pros and cons of EU-accelerated clinical
    development and market access pathways
  • Hear case studies from industry pioneers throughout the world
  • Draw insights from ATMPs that have been commercialised to
    date to inform future market access strategies
  • Anticipate what technologies and infrastructure will be
    needed in the future to mainstream ATMPs
  • Learn about recent pricing and reimbursement strategies
    for cell and gene therapies in the EU and US
  • Deliberate over the real-world challenges and approaches
    to defining and demonstrating therapy value

Download the Conference Preview

Previous Attendee Acclaim:

A great line-up of speakers and the conference
atmosphere enabled excellent discussion.

Global Head, Pricing, Market Access & Policy, Biosimilars, Merck

Excellent conference to bring the commercial and
government contracting perspectives together.

Dept. Director, Government Contracts & Reporting, Bayer

This was a great opportunity to network and share
best practices in our very specialized field.

Finance Manager, Janssen Pharmaceuticals

Every speaker, without exception was excellent.

Director, Patient-Focused Drug Development, TESARO

The robust discussion from all attendees was insightful
and provocative. Rare to have at a conference and
really made it a valuable engagement.

Consumer Marketing Leader, Respiratory, AstraZeneca